Panbela announces closing of approximately $9.0 million public offering

Minneapolis, feb. 01, 2024 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “public warrants”) at a purchase price of $2.06 per share and associated public warrants and $2.059 per pre-funded warrant and associated public warrants. the pre-funded warrants have an exercise price of $0.001 per share. the public warrants have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. the public warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.
PBLA Ratings Summary
PBLA Quant Ranking